Amidst large in­vest­ment from par­ent com­pa­ny, Sam­sung Bi­o­log­ics seeks to ramp up biotech fund­ing

Dur­ing End­points News’ time in San Diego for #BIO22, it was hard to miss all the Sam­sung Bi­o­log­ics signs plas­tered along­side the high­way to the air­port, adorn­ing near­ly every lamp post. How­ev­er, ad­ver­tis­ing is not the on­ly place where Sam­sung is look­ing to spend.

Last month, it was re­port­ed that South Ko­rea’s Sam­sung Group raised spend­ing by more than 30% to KRW 450 tril­lion, or around $360 bil­lion, to in­vest in sev­er­al lines of busi­ness in­clud­ing elec­tron­ics and biotech, among oth­ers. Sam­sung Bi­o­log­ics CEO John Rim spoke to End­points at #BIO22 to dis­cuss how this in­vest­ment will af­fect the biotech arms of one of South Ko­rea’s largest con­glom­er­ates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER